Telephone
61.3.9639.6036
Address
Level 38 55 Collins Street Melbourne, Victoria (VIC) 3000
Description
Mesoblast Ltd. is a biopharmaceutical company, which engages in the research, development, and market of mesenchymal lineage adult stem cell technology platform. Its medicines target cardiovascular diseases, spine orthopedic disorders, oncology and hematology, immune-mediated, and inflammatory diseases. The company was founded by Silviu Itescu on June 8, 2004 and is headquartered in Melbourne, Australia.
Market Cap
PE
EV/EBITDA
DIV Yield
Franking
Ex Dividend Date (est.)
52 weeks range
Low 0.88 - 3.37
Trade Value (12mth)
US$1,935,352.00
1 week
-3.75%
1 month
3.76%
YTD
-46.42%
1 year
66.2%
All time high
9.42
EPS 3 yr Growth
-42.50%
EBITDA Margin
-917.70%
Operating Cashflow
-$56m
Free Cash Flow Return
-9.50%
ROIC
-15.00%
Interest Coverage
-2.40
Quick Ratio
1.20
Shares on Issue (Fully Dilluted)
1142m
HALO Sector
Healthcare
Next Company Report Date
27-Aug-25
Ex Dividend Date (est.)
N/A
Next Dividend Pay Date (est.)
N/A
Reporting Currency
USD
Short Sell (% of issue)
6.62
Date | Announcements |
---|---|
16 June 25 |
Ceasing to be a substantial holder
×
Ceasing to be a substantial holder |
12 June 25 |
Mesoblast Maintains Momentum with FDA
×
Mesoblast Maintains Momentum with FDA |
06 June 25 |
Becoming a substantial holder
×
Becoming a substantial holder |
05 June 25 |
Becoming a substantial holder
×
Becoming a substantial holder |
03 June 25 |
Ceasing to be a substantial holder
×
Ceasing to be a substantial holder |
03 June 25 |
Becoming a substantial holder
×
Becoming a substantial holder |
15 May 25 |
FDA Provides Ryoncil 7 Years Orphan-Drug Exclusive Approval
×
FDA Provides Ryoncil 7 Years Orphan-Drug Exclusive Approval |
14 May 25 |
Becoming a substantial holder
×
Becoming a substantial holder |
09 May 25 |
Ceasing to be a substantial holder
×
Ceasing to be a substantial holder |
08 May 25 |
Becoming a substantial holder
×
Becoming a substantial holder |
07 May 25 |
Ceasing to be a substantial holder
×
Ceasing to be a substantial holder |
02 May 25 |
Becoming a substantial holder
×
Becoming a substantial holder |
30 April 25 |
Quarterly Activities/Appendix 4C Cash Flow Report
×
Quarterly Activities/Appendix 4C Cash Flow Report |
29 April 25 |
Director Appointment
×
Director Appointment |
29 April 25 |
Initial Director's Interest Notice
×
Initial Director's Interest Notice |
24 April 25 |
Appendix 3Y for Gregory George
×
Appendix 3Y for Gregory George |
17 April 25 |
Mesoblast Extends Ryoncil Payer Coverage To 104M US Lives
×
Mesoblast Extends Ryoncil Payer Coverage To 104M US Lives |
14 April 25 |
Notification regarding unquoted securities - MSB
×
Notification regarding unquoted securities - MSB |
14 April 25 |
Application for quotation of securities - MSB
×
Application for quotation of securities - MSB |
14 April 25 |
Notification regarding unquoted securities - MSB
×
Notification regarding unquoted securities - MSB |
14 April 25 |
Notification of cessation of securities - MSB
×
Notification of cessation of securities - MSB |
08 April 25 |
Notification regarding unquoted securities - MSB
×
Notification regarding unquoted securities - MSB |
08 April 25 |
Appendix 3Y - Silviu Itescu, Eric Rose and Philip Krause
×
Appendix 3Y - Silviu Itescu, Eric Rose and Philip Krause |
04 April 25 |
Mesoblast Cell Therapy Products Not Subject to U.S. Tariffs
×
Mesoblast Cell Therapy Products Not Subject to U.S. Tariffs |
03 April 25 |
Meeting Requested with FDA on Revascor Accelerated Approval
×
Meeting Requested with FDA on Revascor Accelerated Approval |
Load More
Load Less
Historical data
Forecast data
Load More
Load Less
Historical data
Forecast data
Load More
Load Less
Historical data
Forecast data
Load More
Load Less
Percent of Issue
Value ($M)
Prior Change
7 Day Change
1 Month Change
3 Month Change
Access data on short interest, stock performance, and potential short-selling candidates across various markets to make informed decisions and optimize your trading strategies.
Unlock true investor intelligence
Research, trade and manage global markets from one place with HALO Global. It’s trading - the way you want it.
Get the latest insights and hot tips delivered right to your inbox
HALO Technologies Pty Ltd ABN 54 623 830 866 is a Corporate Authorised Representative No 1261916 of Macrovue Pty Ltd ABN 98 600 022 679 AFSL 484264. Macrovue Pty Ltd is a wholly owned subsidiary of HALO Technologies Pty Ltd.